Objective: This study aimed to overview and assess the effectiveness of the policies and regulations that have governed new drug access in Korea, and to propose policies to enhance patient access to drugs, particularly for new innovative medicines. Methods: We approached drug access issues in two perspectives: approval lag (or availability) and reimbursement lag (or affordability). The issues were identified and evaluated through the review of literature, public documents, reports published by the government agencies and private organizations, and news articles. Results: To shorten approval lag, it is recommended to hire and train more reviewers at the Ministry of Food and Drug Safety. Increasing user fees to a realistic level can facilitate this process. To reduce reimbursement lag, flexible incremental cost-effectiveness ratio threshold, alternative cost-effectiveness evaluation, and establishment of funding source other than the national health insurance are identified as the areas to be improved. Conclusion: The current policies and regulations had to be supplemented by new systems to drastically promote patient accessibility to new drugs, consequently in order to promote national public health.
목차
ABSTRACT 연구 방법 연구 결과 의약품 허가 지연 의약품 허가 지연 현황: 문제점 의약품 보험 급여 지연 한국의 의약품 보험 급여 지연 현황: 문제점 의약품 허가 지연 개선을 위한 제안 의약품 급여 지연 개선을 위한 제안 고찰 결론 감사의 말씀 이해상충 참고문헌
키워드
Access to new drugsregulatory approvalnational reimbursementcost- effectiveness evaluationincremental costeffectiveness ratio threshold
저자
최유나 [ Yoona Choi | 서울대학교 융합과학기술대학원 응용바이오공학과, 서울대학교 신약개발융합연구센터 ]
이형기 [ Howard Lee | 서울대학교 의과대학대학원 임상약리학협동과정, 서울대학교병원 임상약리학과, 서울대학교 융합과학기술대학원 분자의학 및 바이오제약학과, 서울대학교 신약개발 융합연구센터 ]
Corresponding Author